David Russell‐Jones

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

David Russell‐Jones, Allan Vaag, O. Schmitz et al. · Diabetologia · 2009 · 829 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Simon Heller, John B. Buse, Miles Fisher et al. · The Lancet · 2012 · 401 citations

Medicine, Endocrinology, Pharmacology +15

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

David Russell‐Jones, Robert Cuddihy, M Hanefeld et al. · Diabetes Care · 2011 · 338 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The Effects of 10 Years of Recombinant Human Growth Hormone (GH) in Adult GH-Deficient Patients

James Gibney, Jennifer Wallace, T.J. Spinks et al. · The Journal of Clinical Endocrinology & Metabolism · 1999 · 313 citations

Agriculture, Endocrinology, Nutrition +15

Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes

Philip Home, Paul B. Bartley, David Russell‐Jones et al. · Diabetes Care · 2004 · 257 citations · Full text

Medicine, Endocrinology, Internal Medicine +17